Related references
Note: Only part of the references are listed.c-Raf, but Not B-Raf, Is Essential for Development of K-Ras Oncogene-Driven Non-Small Cell Lung Carcinoma
Rafael B. Blasco et al.
CANCER CELL (2011)
Targeted Therapies for Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2011)
The Transforming Growth Factor-Beta (TGF-β) Mediates Acquisition of a Mesenchymal Stem Cell-Like Phenotype in Human Liver Cells
Laia Caja et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage
Victoria Tovar et al.
JOURNAL OF HEPATOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
David A. Guertin et al.
CANCER CELL (2009)
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
Pippa Newell et al.
JOURNAL OF HEPATOLOGY (2009)
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma
Derek Y. Chiang et al.
CANCER RESEARCH (2008)
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2008)
Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer
Cedric Coulouarn et al.
HEPATOLOGY (2008)
Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis
Kenneth K. Tanabe et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Experimental models of hepatocellular carcinoma
Philippa Newell et al.
JOURNAL OF HEPATOLOGY (2008)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Enabling personalized cancer medicine through analysis of gene-expression patterns
Laura J. van 't Veer et al.
NATURE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
Yujin Hoshida et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma
Laura Gramantieri et al.
LIVER INTERNATIONAL (2007)
Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2007)
The human disease network
Kwang-Il Goh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Genomics and signaling pathways in hepatocellular carcinoma
Augusto Villanueva et al.
SEMINARS IN LIVER DISEASE (2007)
Disrupting insulin-like growth factor signaling as a potential cancer therapy
Deepali Sachdev et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Hypomethylated P4 promoter induces expression of the insulin-like growth factor-II gene in hepatocellular carcinoma in a Chinese population
Shao Hui Tang et al.
CLINICAL CANCER RESEARCH (2006)
Activation of the hedgehog pathway in human hepatocellular carcinomas
Shuhong Huang et al.
CARCINOGENESIS (2006)
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype
Pal Kaposi-Novak et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC
DF Calvisi et al.
GASTROENTEROLOGY (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1
WH Chappell et al.
CELL CYCLE (2005)
β-catenin mutations and expression, 249serine p53 tumor suppressor gene mutation, and hepatitis B virus infection in southern African Blacks with hepatocellular carcinoma
H Elmileik et al.
JOURNAL OF SURGICAL ONCOLOGY (2005)
Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma
JS Campbell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance
A Sangiovanni et al.
GASTROENTEROLOGY (2004)
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma
RTP Poon et al.
BRITISH JOURNAL OF SURGERY (2004)
Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma
N Mitsuhashi et al.
HEPATOLOGY (2003)
Epidermal growth factor receptor: mechanisms of activation and signalling
RN Jorissen et al.
EXPERIMENTAL CELL RESEARCH (2003)
Wnt signaling in hepatocellular carcinoma: Analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes
J Cui et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2003)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
JM Llovet et al.
HEPATOLOGY (2003)
Sustained loss of a neoplastic phenotype by brief inactivation of MYC
M Jain et al.
SCIENCE (2002)
Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma
H Yoshiji et al.
HEPATOLOGY (2002)